



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2381006 A1 2001/03/22

(21) **2 381 006**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2000/09/14

(87) Date publication PCT/PCT Publication Date: 2001/03/22

(85) Entrée phase nationale/National Entry: 2002/03/15

(86) N° demande PCT/PCT Application No.: US 2000/025272

(87) N° publication PCT/PCT Publication No.: 2001/019161

(30) Priorité/Priority: 1999/09/17 (60/154,546) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/09, A61K 31/7052, A61K 38/18,
A61K 48/00, C12N 15/18


(71) Demandeur/Applicant:
ISIS PHARMACEUTICALS, INC., US

(72) Inventeurs/Inventors:
DEAN, NICHOLAS M., US;
MURRAY, SUSAN F., US

(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : MODULATION ANTISENS DE L'EXPRESSION DU TGF-BETA

(54) Title: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR- β EXPRESSION



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

(10) International Publication Number
PCT
WO 01/19161 A2

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/US00/25272

(22) International Filing Date:
14 September 2000 (14.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/154,546 17 September 1999 (17.09.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(71) Applicant (*for all designated States except US*): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

Published:
— *With declaration under Article 17(2)(a); without classification and without abstract; title not checked by the International Searching Authority.*

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **DEAN, Nicholas, M.** [GB/US]; 2110 Whisperwind Lane, Olivenheim, CA 92024 (US). **MURRAY, Susan, F.** [US/US]; 12348 Ann-O-Reno Lane, Poway, CA 92064 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: **LICATA, Jane, Massey** et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).



WO 01/19161 A2

(54) Title: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR- β EXPRESSION

(57) Abstract:

-1-

**ANTISENSE MODULATION OF TRANSFORMING GROWTH
FACTOR- β EXPRESSION**

This application claims the benefit of U.S.
5 Provisional Application No. 60/154,546 filed September 17,
1999.

FIELD OF THE INVENTION

The present invention provides compositions and
methods for modulating the expression of transforming
10 growth factor- β (TGF- β). In particular, this invention
relates to antisense compounds, particularly
oligonucleotides, specifically hybridizable with nucleic
acids encoding human TGF- β . Such oligonucleotides have
been shown to modulate the expression of TGF- β .

15 **BACKGROUND OF THE INVENTION**

Transforming growth factor- β (TGF- β) is a cytokine
which regulates biological processes such as cell
proliferation, differentiation and immune reaction. It has
been found to have many actions in tissue repair,
20 stimulating the deposition of extracellular matrix in
multiple ways. TGF- β stimulates the synthesis of matrix
proteins including fibronectin, collagens and
proteoglycans. It also blocks the degradation of matrix by
inhibiting protease secretion and by inducing the
25 expression of protease inhibitors. It also facilitates
cell-matrix adhesion and matrix deposition via modulation
of expression of integrin matrix receptors, and lastly TGF-
 β also upregulates its own expression. TGF- β exists in
three isoforms in mammals: TGF- β 1, -2 and -3. These
30 function similarly in vitro.

Fibrosis is a pathological process, usually resulting
from injury, which can occur in any organ. Excessive
amounts of extracellular matrix accumulate within a tissue,
forming scar tissue which causes dysfunction and,
35 potentially, organ failure. Fibrosis can be either chronic

-2-

or acute. Chronic fibrosis includes fibrosis of the major organs, most commonly liver, kidney and/or heart, and normally has a genetic or idiopathic origin. Progressive fibrosis of the kidney is the main cause of chronic renal
5 disease. In diabetics, fibrosis within glomeruli (glomerulosclerosis) and between tubules (tubulointerstitial fibrosis) causes the progressive loss of renal function that leads to end-stage renal disease. Fibrotic lung disorders include some 180 different
10 conditions and result in severe impairment of lung function.

Acute fibrosis is associated with injury, often as a result of surgery. Surgical adhesion represents the largest class of acute fibrosis. Surgery often results in excessive
15 scarring and fibrous adhesions. It is estimated that over 90% of post-surgical patients are affected by adhesions. Abdominal adhesions can lead to small bowel obstruction and female infertility. Fibrosis after neck and back surgery (laminectomy, discectomy) can cause significant pain.
20 Fibrosis after eye surgery can impair vision. Pericardial adhesions after coronary bypass surgery, fibrosis after organ transplant rejection and general scarring after plastic surgery are other examples. This represents a major unmet medical need.

25 Antisense and other inhibitors of TGF- β have been used to elucidate the role of TGF- β s in cancer, anaphylaxis, fibrosis and other conditions. As examples:

Dzau (WO 94/26888) discloses use of antisense sequences which inhibit the expression of cyclins and
30 growth factors including TGF- β_1 , TGF, bFGF, PDGF for inhibiting vascular cellular activity of cells associated with vascular lesion formation in mammals.

Shen et al. discloses use of phosphorothioate antisense oligonucleotides targeted to TGF- β_2 to reduce

-3-

TGF- β 2 expression in U937 cells (Bioorg. Med. Chem. Lett., 1999, 9, 13-18).

Schuftan et al. (1999, *Eur. J. Clin Invest.*, 29, 519-528) disclose use of α 2-macroglobin or antisense to TGF- β 1
5 to reduce extracellular matrix synthesis in cultured rat hepatic stellate cells.

Kim et al. have used antisense oligonucleotides targeted to TGF- β 1 to inhibit passive cutaneous anaphylaxis and histamine release. 1999, *J. Immunol.* 162, 4960-4965.

10 Kim et al. have also used an antisense TGF- β 1 oligodeoxynucleotide to inhibit wound-induced expression of TGF- β 1 mRNA in mouse skin. *Pharmacol. Res.*, 1998, 37, 289-293.

Liu et al. used TGF- β antibody or antisense to TGF- β 1
15 to inhibit secretion of plasminogen activator inhibitor-1 in EGR-1 regulated cells. 1999, *J. Biol. Chem.* 274, 4400-4411. Arteaga et al. used antibodies or antisense oligonucleotides targeted to TGF- β 2 to enhance sensitivity of cancer cells to NK cells in the presence of tamoxifen.
20 1999, *J. Nat. Cancer Inst.* 91, 46-53.

Tzai et al. , 1998, *Anticancer Res.*, 18, 1585-1589, used antisense oligonucleotides specific for TGF- β 1 to inhibit in vitro and in vivo growth of murine bladder cancer cells.

25 The role of TGF- β in diabetic nephropathy is reviewed in Hoffman, et al., 1998, *Electrolyte Metab.*, 24, 190-196.

Neutralizing anti-TGF- β antibodies or antisense oligonucleotides directed to TGF- β 1 are reported to prevent the hypertrophic effects of high glucose and the
30 stimulation of matrix synthesis in renal cells.

Antisense phosphorothioate oligodeoxynucleotides targeted to TGF- β 3 were used by Nakajima et al. (1998, *Japan. Dev. Biol.*, 194, 99-113; abstract only) and others to

-4-

block transformation of atrioventricular canal endothelial cells into invasive mesenchyme.

Chung et al. (US Patent 5,683,988) disclose and claim particular antisense oligodeoxynucleotides targeted to TGF- β and use of these to inhibit scarring.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding TGF- β , and which modulate the expression of TGF- β . Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of TGF- β in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of TGF- β by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding TGF- β , ultimately modulating the amount of TGF- β produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding TGF- β . As used herein, the terms "target nucleic acid" and "nucleic acid encoding TGF- β " encompass DNA encoding TGF- β , RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal

-5-

function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of TGF- β . In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene product. In the context of the present invention, inhibition is a preferred form of modulation of gene expression and mRNA is a preferred target. Further, since many genes (including TGF- β) have multiple transcripts, "modulation" also includes an alteration in the ratio between gene products, such as alteration of mRNA splice products.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding TGF- β . The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur

-6-

such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding TGF- β , regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of

-7-

such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination
5 codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region,"
10 which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to
15 the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in
20 the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated
25 guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

30 Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced

- 8 -

together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where
5 an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds
10 targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired
15 effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example,
20 adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

"Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is
25 capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a
30 sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing

-9-

such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, or in the case of *in vitro* assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes of cells, tissues and animals, especially humans.

-10-

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides
5 composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms
10 because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form
15 of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30
20 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside
25 is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that
30 include a pentofuranosyl sugar, the phosphate group can be linked to either the 2'-, 3'- or 5'- hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends

-11-

of this linear polymeric structure can be further joined to form a circular structure. However, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3'-5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages

-12-

include, but are not limited to, U.S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patents 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.

-13-

The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patents 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. Patent 5,489,677, and the amide backbones of the above referenced U.S. Patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C_1

-14-

to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides
5 comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino,
10 substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred
15 modification includes an alkoxyalkoxy group, 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504). A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂
20 group, also known as 2'-DMAOE.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3'
25 position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents
30 that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,0531

-15-

5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or
5 substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine
10 (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil
15 and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-
20 methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science*
25 *And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Crooke, S.T., and Lebleu, B. eds., *Antisense Research and Applications*, CRC
30 Press, Boca Raton, 1993, pp. 289-302. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-

-16-

azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well as U.S. Patents 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,681,941; and 5,750,692, each of which is herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-

-17-

Behmoaras et al., *EMBO J.*, **1991**, *10*, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, *259*, 327-330; Svinarchuk et al., *Biochimie*, **1993**, *75*, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, *18*, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, *14*, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, *1264*, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, *277*, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Patents 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated

-18-

in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds.

"Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Patents 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355;

-19-

5,652,356; and 5,700,922, each of which is herein incorporated by reference.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized *in vitro* and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the *in vivo* synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Patents 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of

-20-

such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for
5 example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that
10 is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE
15 [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 or in WO 94/26764.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the
20 desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as
25 cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et
30 al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be

-21-

regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility
5 in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of
10 the invention. These include organic or inorganic acid salts of the amines. Preferred addition salts are acid salts such as the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art
15 and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic
20 acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid,
25 mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embolic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or
30 aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic aci, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic

-22-

acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of
5 compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are
10 also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as
15 spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric
20 acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid,
25 polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and
30 as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of TGF- β is treated by administering antisense compounds in accordance with this invention. The compounds

-23-

of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding TGF- β , enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding TGF- β can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of TGF- β in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal, intradermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g.,

-24-

intrathecal or intraventricular, administration.

Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

5 Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the
10 like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

 Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets.
15 Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers,
20 diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

 Pharmaceutical compositions and/or formulations comprising the oligonucleotides of the present invention
25 may also include penetration enhancers in order to enhance the alimentary delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et
30 al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). One or more penetration enhancers from one or more of these broad categories may be included.

-25-

Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, 5 tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arichidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (i.e., oleate, 10 laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; El-Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654). Examples of some presently preferred fatty acids are sodium caprate and sodium laurate, used singly or in combination at concentrations of 0.5 to 5%.

The physiological roles of bile include the 20 facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pages 934-935). Various natural bile salts, and their 25 synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. A presently preferred bile salt is chenodeoxycholic acid (CDCA) (Sigma Chemical Company, St. 30 Louis, MO), generally used at concentrations of 0.5 to 2%.

Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex

-26-

formulations. Preferred combinations include CDCA combined with sodium caprate or sodium laurate (generally 0.5 to 5%).

Chelating agents include, but are not limited to, 5 disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug* 10 *Carrier Systems*, 1991, 8:2, 92-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51). Chelating agents have the added advantage of also serving as DNase inhibitors.

15 Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-191); and perfluorochemical emulsions, such as FC-43 20 (Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252-257).

Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic* 25 *Drug Carrier Systems*, 1991, 8:2, 92-191); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

As used herein, "carrier compound" refers to a 30 nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological

-27-

activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, 5 can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially 10 phosphorothioated oligonucleotide in hepatic tissue is reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

In contrast to a carrier compound, a "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering 20 one or more nucleic acids to an animal. The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other 25 components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other 30 sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn

-28-

starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch glycolate, etc.); or wetting agents (e.g., sodium lauryl sulphate, etc.). Sustained release oral delivery systems
5 and/or enteric coatings for orally administered dosage forms are described in U.S. Patents 4,704,295; 4,556,552; 4,309,406; and 4,309,404.

The compositions of the present invention may additionally contain other adjunct components
10 conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or
15 anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However,
20 such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention.

Regardless of the method by which the antisense compounds of the invention are introduced into a patient,
25 colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the compounds and/or to target the compounds to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes,
30 nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes

-29-

are microscopic spheres having an aqueous core surrounded by one or more outer layer(s) made up of lipids arranged in a bilayer configuration (see, generally, Chonn et al., *Current Op. Biotech.*, **1995**, *6*, 698-708).

5 Certain embodiments of the invention provide for liposomes and other compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents
10 include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine
15 (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pp. 1206-1228. Anti-inflammatory
20 drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck*
25 *Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pp. 2499-2506 and 46-49, respectively. Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.
30 In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds

-30-

targeted to a second nucleic acid target. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

-31-

EXAMPLES**Example 1****Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Deoxy and 2'-alkoxy amidites**

5 2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl
phosphoramidites were purchased from commercial sources
(e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling
VA). Other 2'-O-alkoxy substituted nucleoside amidites are
prepared as described in U.S. Patent 5,506,351, herein
10 incorporated by reference. For oligonucleotides
synthesized using 2'-alkoxy amidites, the standard cycle
for unmodified oligonucleotides was utilized, except the
wait step after pulse delivery of tetrazole and base was
increased to 360 seconds.

15 Oligonucleotides containing 5-methyl-2'-deoxycytidine
(5-Me-C) nucleotides were synthesized according to
published methods (Sanghvi, et. al., *Nucleic Acids
Research*, 1993, 21, 3197-3203] using commercially available
phosphoramidites (Glen Research, Sterling VA or ChemGenes,
20 Needham MA).

2'-Fluoro amidites**2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as
described previously by Kawasaki, et. al., *J. Med. Chem.*,
25 1993, 36, 831-841 and U.S. Patent 5,670,633, herein
incorporated by reference. Briefly, the protected
nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was
synthesized utilizing commercially available 9-beta-D-
arabinofuranosyladenine as starting material and by
30 modifying literature procedures whereby the 2'-alpha-fluoro
atom is introduced by a S_N2-displacement of a 2'-beta-trityl
group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine
was selectively protected in moderate yield as the 3',5'-

-32-

ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are

-33-

prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved
10 carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the
15 residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 hours) to give a solid that was crushed to a light tan powder (57 g,
20 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions or purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white
25 solid, mp 222-4°C.

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel
30 and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L).

-34-

The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/Acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

10 **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of 15 dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the 20 reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, 25 filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional 30 was obtained from the impure fractions to give a total yield of 183 g (57%).

-35-

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 hours using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was

-36-

stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed
5 with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

10 A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL).
15 The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue
20 was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

25 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the
30 reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300

-37-

mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions were
5 evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L).
10 Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction
15 mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were combined, dried over MgSO_4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column
20 using EtOAc/Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

Example 2

Oligonucleotide synthesis

25 Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as per the
30 phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation

-38-

wait step was increased to 68 seconds and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 hr), the oligonucleotides were purified by precipitating
5 twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution.

Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

10 Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or
15 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared
20 as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein
25 incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as
30 described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also

-39-

identified as MMI linked oligonucleosides, methylenedi-methylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked
5 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides; also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,
10 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

15 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

20 Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in *Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23*. They may also be prepared in accordance
25 with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

30 Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked

-40-

nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped
5 oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl
10 phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphor-
15 amidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The
20 fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hours at room temperature is then done to deprotect
25 all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hours at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted
30 on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

-41-

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

5 [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

10 **[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above
15 procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization
20 utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Patent
25 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column
30 (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides were purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes

-42-

ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides are synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages are afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages are generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites are purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides are cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product is then re-suspended in sterile water to afford a master plate from which all

-43-

analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8**Oligonucleotide Analysis - 96 Well Plate Format**

5 The concentration of oligonucleotide in each well is assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products is evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACEJ MDQ) or, for
10 individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACEJ 5000, ABI 270). Base and backbone composition is confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates are diluted from the master plate using single and
15 multi-channel robotic pipettors. Plates are judged to be acceptable if at least 85% of the compounds on the plate are at least 85% full length.

Example 9**Cell culture and oligonucleotide treatment**

20 The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR, RNase protection assay (RPA) or Northern
25 blot analysis. The following four human cell types are provided for illustrative purposes, but other cell types can be routinely used.

T-24 cells:

 The transitional cell bladder carcinoma cell line T-
30 24 is obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells are routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal

-44-

calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and
5 dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates
10 and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 is obtained from the American Type Culture Collection (ATCC) (Manassas,
15 VA). A549 cells are routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life
20 Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) are obtained
25 from the Clonetics Corporation (Walkersville MD). NHDFs are routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells are maintained for up to 10 passages as recommended by the supplier.

30 HEK cells:

Human embryonic keratinocytes (HEK) are obtained from the Clonetics Corporation (Walkersville MD). HEKs are routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as

-45-

recommended by the supplier. Cells are routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

5 When cells reached 80% confluency, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 200 μ L OPTI-MEMJ-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEMJ-1 containing 3.75 μ g/mL LIPOFECTINJ (Gibco BRL) and
10 the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after oligonucleotide treatment.

Example 10

15 Analysis of oligonucleotide inhibition of TGF- β expression

Antisense modulation of TGF- β expression can be assayed in a variety of ways known in the art. For example, TGF- β mRNA levels can be quantitated by Northern blot analysis, RNase protection assay (RPA), competitive
20 polymerase chain reaction (PCR), or real-time PCR (RT-PCR). RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 1, John Wiley & Sons, Inc., 1993, pp.
25 4.1.1-4.2.9 and 4.5.1-4.5.3. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 1, John Wiley & Sons, Inc., 1996, pp. 4.2.1-4.2.9. Real-time quantitative (PCR) can be conveniently accomplished using
30 the commercially available ABI PRISMJ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's

-46-

instructions. Other methods of PCR are also known in the art.

TGF- β protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA, flow cytometry or fluorescence-activated cell sorting (FACS). Antibodies directed to TGF- β can be identified and obtained from a variety of sources, such as PharMingen Inc., San Diego CA, or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 11.12.1-11.12.9. Preparation of monoclonal antibodies is taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 11.4.1-11.11.5.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1998, pp. 10.16.1-10.16.11. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1997, pp. 10.8.1-10.8.21. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 2, John Wiley & Sons, Inc., 1991, pp. 11.2.1-11.2.22.

30 **Example 11**

Poly(A)+ mRNA isolation

Poly(A)+ mRNA is isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for

-47-

poly(A)+ mRNA isolation are taught in, for example, Ausubel, et al., *Current Protocols in Molecular Biology*, Volume 1, John Wiley & Sons, Inc., 1993, pp. 4.5.1-4.5.3. Briefly, for cells grown on 96-well plates, growth medium
5 is removed from the cells and each well is washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) is added to each well, the plate is gently agitated and then incubated at room temperature for
10 five minutes. 55 μ L of lysate is transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates are incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate is
15 blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C is added to each well, the plate is incubated on a 90°C hot plate for 5 minutes, and the eluate is then transferred to a fresh 96-well
20 plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

25 Total RNA Isolation

Total mRNA is isolated using an RNEASY 96J kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium is removed
30 from the cells and each well is washed with 200 μ L cold PBS. 100 μ L Buffer RLT is added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol is then added to each well and the contents mixed by pipetting three times up and down. The samples are then

-48-

transferred to the RNEASY 96J well plate attached to a QIAVACJ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum is applied for 15 seconds. 1 mL of Buffer RW1 is added to each well of the RNEASY 96J plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE is then added to each well of the RNEASY 96J plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash is then repeated and the vacuum is applied for an additional 10 minutes. The plate is then removed from the QIAVACJ manifold and blotted dry on paper towels. The plate is then re-attached to the QIAVACJ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA is then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step is repeated with an additional 60 μ L water.

Example 13**Real-time Quantitative PCR Analysis of TGF- β mRNA Levels**

Quantitation of TGF- β mRNA levels is determined by real-time quantitative PCR using the ABI PRISMJ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to

-49-

the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are
5 intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR
10 amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved
15 from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISMJ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples
20 generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents are obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions are carried out by
25 adding 25 μ L PCR cocktail (1x TAQMANJ buffer A, 5.5 mM $MgCl_2$, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLDJ, and 12.5 Units MuLV reverse transcriptase) to 96 well plates
30 containing 25 μ L poly(A) mRNA solution. The RT reaction is carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLDJ, 40 cycles of a two-step PCR protocol are

-50-

carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Example 14**Antisense inhibition of murine TGF- β 1**

5 Antisense oligonucleotides were designed to hybridize to the mouse TGF- β 1 nucleic acid sequence, using published sequence information (GenBank accession No AJ009862; Locus name MMU009862, provided herein as SEQ ID NO: 1). All oligonucleotides have phosphorothioate backbones and are
10 2'-methoxyethyl (2'-MOE) gapmers.

Table 1**Antisense oligonucleotides targeted to mouse TGF- β 1**

	ISIS #	Nucleotide sequence ¹ (5'--> 3')	SITE on TARGET SEQUENCE ²	SEQ ID NO.
15	105193	TGTCTGGAGGATCCGCGGCG	49	2
	105194	TGCTCCTTTGCCGGCTCCCA	149	3
	105195	CGAGACAGCGCAGTGCCAAG	325	4
20	105196	GGCTCCCGAGGGCTGGTCCG	435	5
	105197	GCAGGAGTCGCGGTGAGGCT	696	6
25	105198	AAAGGTGGGATGCGGAGGCC	801	7
	105199	CAGTAGCCGCAGCCCCGAGG	875	8
	105200	AGTCCCGCGGCTGGCCTCCC	937	9
30	105201	GGCTTCGATGCGCTTCCGTT	992	10
	105202	GGCGGTACCTCCCCCTGGCT	1057	11
35	105203	CGCCTGCCACCCGGTCGCGG	1119	12

- 51 -

	ISIS #	Nucleotide sequence ¹ (5'--> 3')	SITE on TARGET SEQUENCE ²	SEQ ID NO.
	105204	GTCCACCATTAGCACGCGGG	1193	13
	105205	GGCACTGCTTCCCGAATGTC	1282	14
5	105206	GTCAGCAGCCGGTTACCAAG	1411	15
	105207	AGTGAGCGCTGAATCGAAAG	1515	16
	105208	GATGGTGCCCAGGTCGCCCC	1598	17
10	105209	AGGAGCAGGAAGGGCCGGTT	1627	18
	105210	TCCGGTGCCGTGAGCTGTGC	1680	19
	105211	GCCCTTGGGCTCGTGGATCC	1796	20
15	105212	CGCCCGGGTTGTGTTGGTTG	1896	21
	105213	GGCTTGCGACCCACGTAGTA	1969	22
20	105214	GGCGGGGCTTCAGCTGCACT	2030	23
	110409	CGCCCGGGTTGTGCTGGTTG 1 base mismatch to 105212	1896	24
25	110410	GTGCTCCCATTTGAAAGCCGG 8 base mismatch to 105204	1193	25

¹ Emboldened residues, 2'-methoxyethoxy- residues (others are 2'-deoxy-). All C residues, including 2'-MOE and 2'-deoxy residues, are 5-methyl-cytosines.

30 ² Position of first nucleotide at the target site on GenBank accession No AJ009862; Locus name MMU009862, provided herein as SEQ ID NO: 1).

The antisense compounds in the table above were screened by Northern blot at 200 nM oligonucleotide
35 concentration in mouse bEND3 endothelial cells (see Montesano et al., Cell, 1990, 62, 435, and Stepkowski et

-52-

al., *J. Immunol.*, 1994, 153, 5336). Cells were treated with oligonucleotide (200 nM) and 10 μ g/ml of Lipofectin (Life Technologies, Inc., Gaithersburg, MD) for 4 hours. Cells were then washed and allowed to recover for a further 24
 5 hr. RNA was isolated and TGF- β 1 mRNA expression was measured by Northern blotting. The gels were stripped and reprobed for expression of a housekeeping gene (G3PDH) to confirm equal loading. TGF- β 1 levels are expressed as a percent of control activity, normalized to G3PDH. Results
 10 are shown in Table 2.

Table 2

Antisense inhibition of mouse TGF- β 1

	ISIS #	% of Control Activity	% Inhibition	SEQ ID NO.
15	105193	6	94	2
	105194	3	97	3
	105195	20	80	4
20	105196	8	92	5
	105198	19	81	7
25	105199	69	31	8
	105200	18	82	9
	105201	86	14	10
30	105202	209	--	11
	105203	160	--	12

-53-

	ISIS #	% of Control Activity	% Inhibition	SEQ ID NO.
	105204	47	53	13
	105205	12	88	14
5	105206	11	89	15
	105207	31	69	16
10	105208	148	--	17
	105209	20	80	18
	105211	148	---	20
15	105212	16	84	21
	105213	9	91	22
20	105214	10	90	23

Oligonucleotides ISIS 105193, 105194, 105195, 105196, 105198, 105200, 105204, 105205, 105206, 105207, 105209, 105212, 105213 and 105214 gave greater than 50% inhibition of TGF- β 1 mRNA in this experiment and are preferred.

Example 15

Dose response of antisense oligonucleotides targeted to murine TGF- β 1

bEND.3 cells were treated with oligonucleotides at various concentrations with 15 μ g/ml Lipofectin for 4 hours, then washed and allowed to recover for 24 hours. TGF- β 1 mRNA levels were determined by Northern blot

-54-

analysis and normalized to G3PDH levels. Results are shown in Table 3.

Table 3

Dose response of antisense oligonucleotides targeted to
murine TGF- β 1

5

	Oligonucleotide	Dose (nM)	% of Control	% Inhib.
	Lipofectin		100	
10	ISIS 105195			
		25	47	53
		50	35	65
15		100	25	75
		200	18	82
20		300	8	92
	ISIS 105199			
		25	115	--
25		50	126	--
		100	125	--
30		200	103	--
	ISIS 105204			
		25	31	69
35		50	22	78
		100	16	84
40		200	11	89
		300	11	89

-55-

	Oligonucleotide	Dose (nM)	% of Control	% Inhib.
	ISIS 105212			
		25	43	57
5		50	29	71
		100	26	74
		200	18	82
10		300	24	76
	ISIS 105214			
15		25	30	70
		50	17	83
		100	17	83
20		200	11	89
		300	14	86
25				

ISIS 105195, 105204, 105212 and 105214 had IC₅₀s below 25 nM in this experiment and are preferred.

Example 16

"Humanized" mouse TGF- β 1 antisense oligonucleotide

30 It was determined by BLAST analysis (Altschul SF et al., *J. Mol. Biol.* 1990, 215, 403-10) that ISIS 105204, designed to target mouse TGF- β 1, has only a single mismatch to the human TGF- β 1 gene target, and, except for the 5'-most base on the oligonucleotide, is complementary to a
 35 site beginning at nucleotide 1167 on the human target (GenBank accession no. X02812; locus name HSTGFB1; Derynck, R., et al., 1985, *Nature* 316, 701-705). An

-56-

oligonucleotide (**TTCCACCATTAGCACGCGGG**; ISIS 113849; SEQ ID NO: 26) was designed and synthesized which was a complete match to the human target sequence at this site. This compound is a phosphorothioate backbone with 2'-MOE nucleotides shown in bold. All C residues are 5-methyl C.

Example 17**Efficacy of ISIS 105204 in rat kidney cells**

ISIS 105204, designed to target mouse TGF- β 1, was tested in rat NRK kidney cells (available from American Type Culture Collection, Manassas VA). This oligonucleotide has 100% complementarity to the rat TGF- β 1 sequence (GenBank accession no.X52498; locus name RNTGFB1, provided herein as SEQ ID NO: 27). A dose response is shown in Table 4. ISIS 105195, which is targeted to a region of the mouse TGF- β 1 sequence which shares only 9 of 20 nucleobases with the rat sequence, is shown for comparison.

Table 4

Dose response of antisense oligonucleotides targeted to mouse TGF- β 1 in rat NRK cells

20	ISIS #	Dose (nM)	% of Control activity	% Inhibition	SEQ ID NO
	Lipofectin		100	--	
	105195				4
25		100	115	--	
		200	98	2	
30		300	97	3	

-57-

20

ISIS #	Dose (nM)	% of Control activity	% Inhibition	SEQ ID NO
105204				13
	50	56	44	
5	100	50	50	
	200	39	61	

10 **Example 18****Effect of antisense inhibition of TGF- β 1 on fibrotic scarring**

A model for fibrosis has been developed in which osmotic pumps are implanted subcutaneously in rats.

15 Normally the pump becomes encapsulated by fibrotic scar tissue. The effect of antisense inhibition of TGF- β 1 on scarring can be analyzed and quantitated.

2 ml Alzet osmotic pumps (Alza corporation, Palo Alto, CA) were implanted subcutaneously on the back of female Sprague Dawley rats. Four rats per experimental group were implanted with pumps containing PBS, 5 mgs of TGF- β 1 antisense oligonucleotide and 5 mgs of an eight base mismatch control oligonucleotide, ISIS 110410. After 3 weeks the encapsulation tissue surrounding the pump was removed, weighed, snap frozen, and evaluated for TGF- β 1 mRNA by Northern blot analysis or RNase protection assay using the rCK3b template (Pharmingen, San Diego CA) and by immunohistochemistry. For the latter, formalin fixed, paraffin embedded tissues were stained with Masson's Trichrome Stain for Collagen and immunochemical

20

25

30

-58-

localization of oligonucleotide. Frozen tissues were antibody-stained for TGF- β 1 (antibody from Santa Cruz Biotechnologies, Santa Cruz, CA), and EDA Fibronectin (antibody from Harlan Bioproducts, Sussex, England). The
5 antibodies were detected with secondary reagents directly conjugated to HRP and DAB (brown) was used as the substrate.

TGF- β 1 expression in the scar tissue was reduced by greater than 50% after 28-day treatment with ISIS 105204
10 (oligonucleotide dose 15 mg/kg; and to greater than 30% with a dose of 5 mg/kg), as measured by Northern blot analysis of TGF- β 1 mRNA levels. This is shown in Table 5.

Table 5

**Effect of ISIS 105204 on TGF- β 1 expression in rat scar
15 tissue**

Oligonucleotide	% of control	% inhibition	SEQ ID NO
Saline control	100	--	
20 ISIS 110410 (8-base mismatch of 105204)	83	17	25
ISIS 105204	44	56	13

25 Immunohistochemical staining showed that TGF- β 1 protein expression is reduced in scar tissue from mice treated with ISIS 105204. Levels of collagen and fibronectin, which are markers for fibrosis, were also
30 reduced in scar tissue from these mice. Staining also showed a decrease in the number of CD18 positive cells.

Example 19**Antisense oligonucleotides targeted to human TGF- β 1**

Antisense oligonucleotides were designed to hybridize to the human TGF- β 1 nucleic acid sequence, using published sequence information; Derynck, R., et al., 1985, Nature 316, 701-705; GenBank accession number X02812; locus name HSTGFB1, incorporated herein as SEQ ID NO: 28. Oligonucleotides have phosphorothioate backbones and are 2'MOE gapmers. Sequences are shown in Table 6.

10

Table 6**Antisense oligonucleotides targeted to human TGF- β**

ISIS #	Nucleotide sequence ¹ (5'--> 3')	SITE on TARGET SEQUENCE ²	SEQ ID NO:
15 104978	CGACTCCTTCCTCCGCTCCG	113	29
104979	CTCGTCCCTCCTCCCGCTCC	209	30
104980	AAGTCCTGCCTCCTCGCGGG	317	31
20 104981	AAGGGTCTAGGATGCGCGGG	531	32
104982	CTCAGGGAGAAGGGCGCAGT	692	33
25 104983	GCACTGCCGAGAGCGCGAAC	802	34
104984	GTAGCAGCAGCGGCAGCAGC	862	35
104985	ATGGCCTCGATGCGCTTCCG	968	36
30 104986	GCGTAGTAGTCGGCCTCAGG	1136	37
104987	ACCACTGCCGCACAACTCCG	1447	38
35 104988	TCGGCGGCCGGTAGTGAACC	1557	39
104989	GAAGTTGGCATGGTAGCCCT	1788	40

-60-

5 10	ISIS #	Nucleotide sequence ¹ (5'--> 3')	SITE on TARGET SEQUENCE ²	SEQ ID NO:
	104990	GGCGCCCGGGTTATGCTGGT	1875	41
	104991	CTCCACCTTGGGCTTGCGGC	1956	42
	104992	AATGACACAGAGATCCGCAG	2155	43
	104993	TAGATCTAACTACAGTAGTG	2305	44
	104994	CGCCTGGCCTGAACTACTAT	2525	45
	104995	CCCAGGCTGGTCTCAAATGC	2609	46

¹ Emboldened residues, 2'-methoxyethoxy- residues (others are 2'-deoxy-). All C residues, including 2'-MOE and 2'-deoxy residues, are 5-methyl-cytosines.

² Position of first nucleotide at the target site on GenBank accession number X02812; locus name HSTGFB1, provided herein as SEQ ID NO: 28.

20 Oligonucleotides were screened in 293T human kidney cells at a concentration of 200 nM with 10 μ g/ml of Lipofectin for a period of four hours. Cells were washed and allowed to recover for a further 24 hr. At this point RNA was isolated and TGF- β 1 mRNA levels were determined by
25 Ribonuclease Protection Assay (RPA) using the hCK-3 template (Pharmingen, San Diego CA) according to the manufacturer's instructions. TGF- β 1 mRNA levels were normalized to GAPDH and expressed as a percentage of untreated control. Results are shown in Table 7.

-61-

Table 7

Antisense Inhibition of Human TGF- β 1

	ISIS #	% of Control Activity	% Inhibition	SEQ ID NO:
5	104978	150	--	29
	104979	94	6	30
	104980	82	18	31
10	104981	86	14	32
	104982	94	6	33
15	104983	52	48	34
	104985	59	41	36
	104986	59	41	37
20	104987	63	37	38
	104988	71	29	39
25	104989	86	14	40
	104990	57	43	41
	104991	52	48	42
30	104992	47	53	43
	104993	84	16	44
35	104994	60	40	45
	104995	64	36	46
40	105204	23	77	13

-62-

In this experiment ISIS 104983, 104985, 104986, 104990, 104991, 104992, 104994 and 105204 gave at least 40% inhibition of human TGF- β 1 mRNA and are preferred. ISIS 104992 and 105204 gave over 50% inhibition.

5 Example 20

Dose responses of antisense oligonucleotides targeted to human TGF- β 1

ISIS 113849, 105204, 110410 (8 base mismatch of 105204) and 104992 were tested at 50, 100 and 200 nM for ability to inhibit TGF- β 1 mRNA levels. Results are shown in Table 8.

-63-

Table 8

Dose response of oligonucleotides targeted to human TGF- β 1

	ISIS #	Dose (nM)	% of Control Activity	% Inhibition	SEQ ID NO:
5	104992	50	65	35	43
		100	68	32	
		200	93	7	
10	105204	50	31	69	13
		100	16	84	
15		200	23	77	
	110410	50	85	15	25
		100	64	36	
20		200	50	50	
	113849	50	29	71	26
25		100	24	76	
		200	36	64	

30 ISIS 105204 and 113849 had IC₅₀s below 50 nM in this experiment. These oligonucleotides were found to have little effect on TGF- β 2 or TGF- β 3 mRNA levels.

Example 21

Antisense compounds targeted to murine TGF- β 2

35 Antisense oligonucleotides were designed to hybridize to the mouse TGF- β 2 nucleic acid sequence, using published sequence information from GenBank accession number X57413; Miller, D.A., et al., *Mol. Endocrinol.* **1989**, 3, 1108-1114;

locus name MMTGFB2, incorporated herein as SEQ ID NO: 47.
The oligonucleotides are shown in Table 9.

Table 9

Antisense sequences targeted to murine TGF- β 2

5		ISIS #	Nucleotide sequence¹ (5'--> 3')	SITE on TARGET SEQUENCE²	SEQ ID NO.
		104996	GCCGGCAGTTTCAGCAGCTC	34	48
		104997	CTCGCACCTTCCCTAGCTT	259	49
10		104998	TTTCTTGCTCCAGGCGGCCA	362	50
		104999	GAGCAGGCGGCGAGGATCCC	493	51
15		105000	GCCCTGCCTTCCACACGTGT	671	52
		105001	GTGCGGAGTGGCTGATCTGA	830	53
		105002	AAAATGCAACGCGTTCCCAA	1016	54
20		105003	CCGGGACCAGATGCAGGAGC	1247	55
		105004	TCCGGCTTGCCTTCTCCTGC	1451	56
25		105005	GGGTTTTGCAAGCGGAAGAC	1668	57
		105006	CGATGTAGCGCTGGGTGGGA	1754	58
		105007	GGTCTTCCCCTGGTTTTTT	2032	59
30		105008	AAGCTTCGGGATTTATGGTG	2321	60
		105009	ACCGTGATTTTCGTGTCCTG	2478	61
35		105010	GCGGGCTGGAAACAATACGT	2854	62
		105011	CCCCTGGCTTATTTGAGTTC	3075	63
40		105012	ACCGGCTTGCTTAAACTGGC	3297	64

-65-

5	ISIS #	Nucleotide sequence¹ (5'--> 3')	SITE on TARGET SEQUENCE²	SEQ ID NO.
	105013	CAGCCACTTCACGGTCAAAA	3352	65
	105014	ATGGACCCAGGTAGCTCATG	3753	66
5	105015	CACCCGCCACATGACTCACA	3874	67
	105016	TACACCCCATGAGCACCAAA	4097	68

10 ¹ Emboldened residues, 2'-methoxyethoxy- residues (others are 2'-deoxy-). All C residues, including 2'-MOE and 2'-deoxy residues, are 5-methyl-cytosines.

² Position of first nucleotide at the target site on GenBank accession number X57413; Miller,D.A., et al., *Mol. Endocrinol.* **1989**, 3, 1108-1114; locus name MMTGFB2, incorporated herein as SEQ ID NO: 47.

The oligonucleotides shown in Table 9 were screened for the ability to inhibit mouse TGF- β 2 mRNA expression by ribonuclease protection assay (RPA) in mouse R6 +/+ fibroblast cells. Cells were treated with oligonucleotide (200 nM) and 10 μ g/ml of Lipofectin (Life Technologies, Inc.) for 4 hours. Cells were then washed and allowed to recover for a further 24 hours. RNA was isolated and TGF- β 2 mRNA expression was measured by RPA using the mCK3b template (PharMingen, Inc., San Diego CA) according to manufacturer's directions. Results were normalized to GAPDH and expressed as a percent of RNA levels in untreated control cells. Results are shown in Table 10.

-66-

Table 10

Antisense inhibition of mouse TGF- β 2 mRNA expression

	ISIS #	% of control activity	% inhibition	SEQ ID NO:
5	104996	83	17	48
	104997	79	21	49
10	104998	70	30	50
	104999	90	10	51
	105000	64	36	52
15	105001	37	63	53
	105002	51	49	54
20	105003	28	72	55
	105004	52	48	56
	105005	77	23	57
25	105006	53	47	58
	105007	60	40	59
30	105008	55	45	60
	105009	28	72	61
	105010	27	73	62
35	105011	48	52	63
	105012	35	65	64
40	105013	40	60	65
	105014	43	57	66
	105015	64	36	67
45	105016	89	11	68

-67-

ISIS 105001, 105002, 105003, 105004, 105006, 105008, 105009, 105010, 105011, 105012, 105013 and 105014 gave at least about 45% inhibition of TGF- β 2 mRNA expression in this experiment and are preferred. Of these, ISIS 105003, 105009 and 105010 gave at least 70% inhibition.

Interestingly, it was found that oligonucleotides that reduced TGF- β 2 also reduced TGF- β 3 mRNA levels. This is shown in Table 11.

Table 11

Common inhibition of murine TGF- β 2 and TGF- β 3 by antisense oligonucleotides targeted to murine TGF- β 2

ISIS #	% inhibition of TGF- β 2	% inhibition of TGF- β 3	SEQ ID NO:
104996	17	3	48
104997	21	11	49
104998	30	--	50
104999	10	14	51
105000	36	16	52
105001	63	48	53
105002	49	23	54
105003	72	67	55
105004	48	49	56
105005	23	20	57
105006	47	60	58
105007	40	29	59
105008	45	23	60
105009	72	55	61
105010	73	49	62

-68-

	ISIS #	% inhibition of TGF- β 2	% inhibition of TGF- β 3	SEQ ID NO:
	105011	52	57	63
	105012	65	42	64
5	105013	60	55	65
	105014	57	43	66
10	105015	36	52	67
	105016	11	12	68

Example 22**15 Reduction in peritoneal adhesions by antisense inhibition of TGF- β 1**

The surface of the peritoneal cavity and the enclosed organs are coated with a layer of mesothelial cells that are easily damaged by injury or infection. Following injury
 20 (surgery, for example), adhesions form which cause permanent scarring. This scarring can result in bowel obstruction, pain, and/or female infertility. A rat model for peritoneal adhesions has been developed (Williams et al., 1992, *J. Surg. Res.* 52, 65-70). Animal models have
 25 demonstrated that TGF- β promotes the formation of postoperative pelvic adhesions.

In these experiments bilateral uterine injuries were created in 250 gm Sprague Dawley rats by cautery, scraping and crushing. Rats then received 5 mg (20 mg/kg) of an
 30 antisense oligonucleotide (ISIS 105204), 5 mg of a scrambled control oligonucleotide (ISIS 110410) or 1 mL of saline vehicle via intraperitoneal injection.

Uterine adhesions were then graded by masked evaluators using a clinical scale of 0-3 on days 3, 7 and
 35 14 after injury.

-69-

In order to localize the target tissue of the antisense oligonucleotides, an additional group of rats were injected with a reporter oligonucleotide and biopsies were performed on the uterus, liver and kidney of the treated animals. The tissues were then fixed and the reporter oligonucleotide was immunolocalized with a specific antibody. The reporter oligonucleotide was concentrated heavily in the area of uterine injury at 2 hours and persisted in uterine cells at 72 hours indicating that the oligonucleotide does localize to the injured area.

A single dose of the antisense oligonucleotide (ISIS 105204) to TGF- β 1 significantly reduced the severity of peritoneal adhesions, from a mean of 3.0 for control animals to 1.2 for antisense treated animals. A scrambled control oligonucleotide (ISIS 110410) gave a mean adhesion score of 2.4 over the entire study.

Example 23

Effect of antisense inhibition of TGF- β 1 on lung fibrosis

A model of lung fibrosis has been developed using bleomycin to induce pulmonary fibrosis in mice. Wild, JS, SN Giri et al., 1996, Exp. Lung Res. 22, 375-391. Mice receive an intratracheal dose of bleomycin (0.125U/mouse) or saline, followed by treatment with antisense oligonucleotide (i.p.) over 2 weeks. Mice were treated with ISIS 105204 or 110410. RNA was isolated from lungs and TGF- β 1 mRNA levels were determined for mice treated with saline or bleomycin alone, saline or bleomycin plus ISIS 105204, and bleomycin plus the scrambled control ISIS 110410. Results are shown in Table 12. These studies showed a significant reduction of bleomycin-induced lung hydroxyproline content, prolyl hydroxylase and lipid peroxidation. Lung histopathology showed fibrotic lesions to be reduced in bleomycin treated animals receiving the TGF- β 1 oligonucleotide compared to saline or mismatch

-70-

treated animals. Also, RPA (ribonuclease protection assay) analysis revealed a 45% reduction in TGF- β 1 RNA in animals treated with ISIS 105204.

Table 12**5 Effect of antisense inhibition of TGF- β 1 on lung fibrosis**

	Treatment	% of control	% inhibition
	Saline	100	--
10	Saline + 105204	81	19
	Bleomycin	70	30
15	Bleomycin + 110410	73	27
	Bleomycin + 105204	37	63

Example 24**20 Effect of antisense inhibition of TGF- β 1 on conjunctival scarring**

Animal models for a variety of fibrotic diseases and conditions exist. Conjunctival scarring is a major predictor of visual prognosis in a variety of eye conditions, including post-surgical healing. For example, the most common cause of failure of glaucoma filtration surgery is scarring at the bleb and sclerostomy sites. A model of conjunctival scarring in the mouse eye has been developed to investigate potential determinants, modes of prevention and treatments for conjunctival scarring. Reichel et al., 1998, *Br. J. Ophthalmol.* 82, 1072-1077. This model is used to evaluate the effects of locally or systemically delivered antisense to TGF- β on conjunctival scarring.

35 Alternatively, antisense compounds can be administered at the time of trabeculectomy filtration surgery. Animals are anesthetized, and the general glaucoma

-71-

filtration trabeculectomy procedure is followed. A conjunctival flap is raised and a viscoelastic solution (e.g., Healon) is injected into the anterior chamber. A paracentesis stab incision is made using a 75 Beaver blade into the anterior chamber. A sclerotomy is performed through the paracentesis incision using a membrane punch and a peripheral iridectomy is done through the sclerostomy. The conjunctival flap is repositioned and closed with suture in two layers. Oligonucleotide solution (100 μ l of 40 μ M in the case of rabbits, less in mouse or rat) is injected into the bleb by tunneling a 30 gauge needle through the conjunctiva adjacent to the bleb. Animals are sacrificed 24 hours after treatment and eyes are fixed and examined histologically for collagen, fibronectin, and immunohistochemically for TGF- β .

In these experiments Balb-c mice, a highly inbred strain of mice used to produce monoclonal antibodies, were randomly allocated to one of five treatment groups; subconjunctival injection (5 μ l) of 25 μ g or 12.5 μ g of either a TGF- β 1 antisense oligonucleotide (ISIS 105204) or a scrambled control oligonucleotide (ISIS 110410), or the carrier saline control. Cellular distribution of oligonucleotide in glaucoma surgery was assessed following subconjunctival administration of a reporter oligonucleotide into the filtration bleb immediately after surgery in NZW rabbits. Mice and rabbits were assessed clinically and enucleated eyes were analyzed at set time intervals histologically.

At days 3 and 7 mouse eyes (n=4) showed significantly reduced white cell infiltration and collagen fibril deposition in the TGF- β 1 oligonucleotide treated groups compared to controls. There was also a significant decrease in localization of fibroblasts and elastin related

-72-

fibers on days 3,7 and 14 in groups treated with the TGF- β 1 antisense oligonucleotide.

At 7 days mouse eyes (4 eyes/treatment group) showed significantly reduced ($p<0.05$) conjunctival scar formation
5 in the TGF- β 1 treated animals as compared to the control group.

The cellular profile suggested that TGF- β 1 oligonucleotide delayed the development of the wound healing response. Immunohistochemical staining with an
10 antibody specific for the reporter oligonucleotide in rabbit eyes revealed intense and localized staining of the TGF- β 1 oligonucleotide to fibroblasts, epithelial cells and macrophages in the sclera and conjunctiva at the surgical site.

15 **Example 25**

Effect of antisense inhibition of TGF- β 1 on inflammation-human skin xenograft model in the SCID mouse.

Another model used to investigate the processes of inflammation and scarring involves the use of SCID mice
20 transplanted with human skin. SCID mice lack an enzyme necessary to fashion an immune system and can therefore be converted into a model of the human immune system when injected with human cells or tissues. In these experiments human skin (2 cm²) from various surgical procedures (breast
25 reductions or neonatal foreskin) or from cadavers was transplanted onto the side of SCID mice with sutures or surgical staples. After four to six weeks, the mice were bled and tested for Ig to ensure the SCID lineage. After 8 to 10 weeks, the xenograft skin was treated with antisense
30 oligonucleotide, ISIS 105204, SEQ ID NO: 13) in a cream formulation at 48, 24, and 4 hours prior to the injection of 4000U of tumor necrosis factor-alpha (TNF- α). Levels of TGF- β protein were then assayed in the epidermis and dermis of the xenograft skin by immunohistochemical staining 24

-73-

hours after TNF- α injection. Levels were reported as a percentage of the area showing positive staining for the presence of TGF- β protein.

In the epidermis, 3% of the area showed positive
5 staining after treatment with TGF- β antisense
oligonucleotide relative to basal levels of 50% and levels
of 37% for the placebo cream group. This data was shown to
be statistically significant ($P=0.0001$).

In the dermis, TGF- β levels were below 0.5% with
10 basal levels at 2.5% and placebo cream group levels of 2%.

SEQUENCE LISTING

<110> Nicholas M. Dean
Susan F. Murray
ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA
EXPRESSION

<130> ISPH-0489

<150> 1999-09-17

<151> 60/154,546

<160> 68

<210> 1

<211> 2094

<212> DNA

<213> Mus musculus

<221> CDS

<222> (868)...(2040)

<400> 1

```
cgccgcccgc gccgcccttc gcgccccagg ccgtccccct cctcctcccg ccgcggatcc 60
tccagacagc caggcccccg gccggggcag gggggacgcc ccttcggggc acccccggct 120
ctgagccgca ctcgagatcg gcctccgctg ggagccggca aaggagcagc cgaggagccg 180
tccgaggccc cagagtctga gaccagccgc cgccgcaggg aggaggggga ggaggagtgg 240
gaggagggac gagctggttg agagaagagg aaaaaagttt tgagactttt ccgctgctac 300
tgcaagtcag agacgtgggg acttcttggc actgcgctgt ctgcgaagga ggcaggacct 360
gaggactcca gacagccctg ctcaccgtcg tggacactcg atcgctaccc ggcgttcctc 420
agacgcccct attccggacc agccctcggg agccacaaac cccgcctccc gcgaagactt 480
caccaccaag ctggggcgca ccccttgca cccgcccctc cccagcctg cctcttgagt 540
ccctcgcatc ccaggaccct ctctcccccg agaggcagat ctccctcgga cctgctggca 600
gtagctcccc tatttaagaa caccactttt tggatctcag agagcgctca tctcgatttt 660
taccctgggtg gtatactgag acaccttggg gtcagagcct caccgcgact cctgctgctt 720
tctccctcaa cctcaaatta ttcaggacta tcacctacct ttccttggga gacccacccc 780
cacaagccct gcaggggccc ggccctccgca tcccaccttt gccgagggtt cccgctctcc 840
gaagtgccgt ggggcgccgc ctcccc atg ccg ccc tcg ggg ctg cgg cta ctg 894
```

Met Pro Pro Ser Gly Leu Arg Leu Leu
1 5

```
ccg ctt ctg ctc cca ctc ccg tgg ctt cta gtg ctg acg ccc ggg agg 942
Pro Leu Leu Leu Pro Leu Pro Trp Leu Leu Val Leu Thr Pro Gly Arg
10 15 20 25
```

```
cca gcc gcg gga ctc tcc acc tgc aag acc atc gac atg gag ctg gtg 990
Pro Ala Ala Gly Leu Ser Thr Cys Lys Thr Ile Asp Met Glu Leu Val
30 35 40
```

```
aaa cgg aag cgc atc gaa gcc atc cgt ggc cag atc ctg tcc aaa cta 1038
Lys Arg Lys Arg Ile Glu Ala Ile Arg Gly Gln Ile Leu Ser Lys Leu
45 50 55
```

WO 01/19161

PCT/US00/25272

agg ctc gcc agt ccc cca agc cag ggg gag gta ccg ccc ggc ccg ctg	1086
Arg Leu Ala Ser Pro Pro Ser Gln Gly Glu Val Pro Pro Gly Pro Leu	
60 65 70	
ccc gag gcg gtg ctc gct ttg tac aac agc acc cgc gac cgg gtg gca	1134
Pro Glu Ala Val Leu Ala Leu Tyr Asn Ser Thr Arg Asp Arg Val Ala	
75 80 85	
ggc gag agc gcc gac cca gag ccg gag ccc gaa gcg gac tac tat gct	1182
Gly Glu Ser Ala Asp Pro Glu Pro Glu Pro Glu Ala Asp Tyr Tyr Ala	
90 95 100 105	
aaa gag gtc acc cgc gtg cta atg gtg gac cgc aac aac gcc atc tat	1230
Lys Glu Val Thr Arg Val Leu Met Val Asp Arg Asn Asn Ala Ile Tyr	
110 115 120	
gag aaa acc aaa gac atc tca cac agt ata tat atg ttc ttc aat acg	1278
Glu Lys Thr Lys Asp Ile Ser His Ser Ile Tyr Met Phe Phe Asn Thr	
125 130 135	
tca gac att cgg gaa gca gtg ccc gaa ccc cca ttg ctg tcc cgt gca	1326
Ser Asp Ile Arg Glu Ala Val Pro Glu Pro Pro Leu Leu Ser Arg Ala	
140 145 150	
gag ctg cgc ttg cag aga tta aaa tca agt gtg gag caa cat gtg gaa	1374
Glu Leu Arg Leu Gln Arg Leu Lys Ser Ser Val Glu Gln His Val Glu	
155 160 165	
ctc tac cag aaa tat agc aac aat tcc tgg cgt tac ctt ggt aac cgg	1422
Leu Tyr Gln Lys Tyr Ser Asn Asn Ser Trp Arg Tyr Leu Gly Asn Arg	
170 175 180 185	
ctg ctg acc ccc act gat acg cct gag tgg ctg tct ttt gac gtc act	1470
Leu Leu Thr Pro Thr Asp Thr Pro Glu Trp Leu Ser Phe Asp Val Thr	
190 195 200	
gga gtt gta cgg cag tgg ctg aac caa gga gac gga ata cag ggc ttt	1518
Gly Val Val Arg Gln Trp Leu Asn Gln Gly Asp Gly Ile Gln Gly Phe	
205 210 215	
cga ttc agc gct cac tgc tct tgt gac agc aaa gat aac aaa ctc cac	1566
Arg Phe Ser Ala His Cys Ser Cys Asp Ser Lys Asp Asn Lys Leu His	
220 225 230	
gtg gaa atc aac ggg atc agc ccc aaa cgt cgg ggc gac ctg ggc acc	1614
Val Glu Ile Asn Gly Ile Ser Pro Lys Arg Arg Gly Asp Leu Gly Thr	
235 240 245	
atc cat gac atg aac cgg ccc ttc ctg ctc ctc atg gcc acc ccc ctg	1662
Ile His Asp Met Asn Arg Pro Phe Leu Leu Leu Met Ala Thr Pro Leu	
250 255 260 265	
gaa agg gcc cag cac ctg cac agc tca cgg cac cgg aga gcc ctg gat	1710
Glu Arg Ala Gln His Leu His Ser Ser Arg His Arg Arg Ala Leu Asp	
270 275 280	
acc aac tat tgc ttc agc tcc aca gag aag aac tgc tgt gtg cgg cag	1758
Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys Val Arg Gln	
285 290 295	
ctg tac att gac ttt agg aag gac ctg ggt tgg aag tgg atc cac gag	1806
Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp Ile His Glu	
300 305 310	

ccc aag ggc tac cat gcc aac ttc tgt ctg gga ccc tgc ccc tat att 1854
 Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile
 315 320 325

tgg agc ctg gac aca cag tac agc aag gtc ctt gcc ctc tac aac caa 1902
 Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu Ala Leu Tyr Asn Gln
 330 335 340 345

cac aac ccg ggc gct tcg gcg tca ccg tgc tgc gtg ccg cag gct ttg 1950
 His Asn Pro Gly Ala Ser Ala Ser Pro Cys Cys Val Pro Gln Ala Leu
 350 355 360

gag cca ctg ccc atc gtc tac tac gtg ggt cgc aag ccc aag gtg gag 1998
 Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro Lys Val Glu
 365 370 375

cag ttg tcc aac atg att gtg cgc tcc tgc aag tgc agc tga 2040
 Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys Cys Ser *
 380 385 390

agccccgccc cgccccgccc ctccccggcag gcccgggcccc gcccccgccc cgcc 2094

<210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2
 tgtctggagg atccgcggcg 20

<210> 3
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 3
 tgctcctttg ccggctccca 20

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 4
 cgagacagcg cagtgcccaag 20

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 5
 ggctcccagag ggctgggtccg 20

WO 01/19161

PCT/US00/25272

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 6
 gcaggagtcg cggtgaggct 20

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 7
 aaagggtggga tgcggaggcc 20

<210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 8
 cagtagccgc agccccgagg 20

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9
 agtcccgcgg ctggcctccc 20

<210> 10
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10
 ggcttcgatg cgcttccggt 20

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 11
 ggcggtacct ccccctggct 20

<210> 12
 <211> 20
 <212> DNA

WO 01/19161

PCT/US00/25272

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12

cgcctgccac ccggtcgcgg

20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 13

gtccaccatt agcacgcggg

20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 14

ggcactgctt cccgaatgtc

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 15

gtcagcagcc ggttaccaag

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 16

agtgagcgct gaatcgaaag

20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17

gatggcgccc aggtcgcccc

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

WO 01/19161

PCT/US00/25272

<400> 18
 aggagcagga agggccggtt 20

<210> 19
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
 tccggtgccg tgagctgtgc 20

<210> 20
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20
 gcccttgggc tcgtggatcc 20

<210> 21
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21
 cgcccggggtt gtgttggttg 20

<210> 22
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22
 ggcttgcgac ccacgtagta 20

<210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23
 ggcggggcctt cagctgcact 20

<210> 24
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24
 ccacgtagta gacgatgggc 20

<210> 25
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25
 gtccaccatt agcacgcggg 20

<210> 26
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26
 gtccaccatt agcacgcggg 20

<210> 27
 <211> 1585
 <212> DNA
 <213> Rattus norvegicus

<221> CDS
 <222> (413) ... (1585)

<400> 27
 accgcctccc gcaaagactt caccceaaag ctggggcgca ccccttgac gccaccctcc 60
 cccagcctg cttcttgagt ccccgcatc ccaggaccct ctctcctctg ggaggccgat 120
 ctccctcgga cctgctggca atagcttcct atttaagaac accccacttt tgggtcccag 180
 agagcgctca tctcgatttt tatcccggtg gcatactgag acactctggt gtcagagcgt 240
 caccgcgact cctgctgctt tctccctcaa cctcaaatta ttcaggacta tcacctacct 300
 ttccttgagg gacccacccc caccceacaa gccctgcagg ggcggggcct ccgcatccca 360
 cctttgcccg gggttcgcgc tctccgaagt tccgtggggc gccgcctccc cc atg ccg 418
 Met Pro
 1

ccc tcg ggg ctg cgg ctg ctg ccg ctt ctg ctc cca ctc ccg tgg ctt 466
 Pro Ser Gly Leu Arg Leu Leu Pro Leu Leu Leu Pro Leu Pro Trp Leu
 5 10 15

cta gtg ctg acg ccc ggg agg cca gcc gcg gga ctc tcc acc tgc aag 514
 Leu Val Leu Thr Pro Gly Arg Pro Ala Ala Gly Leu Ser Thr Cys Lys
 20 25 30

acc atc gac atg gag ctg gtg aaa cgg aag cgc atc gaa gcc atc cgt 562
 Thr Ile Asp Met Glu Leu Val Lys Arg Lys Arg Ile Glu Ala Ile Arg
 35 40 45 50

ggc cag atc ctg tcc aaa cta agg ctc gcc agt ccc ccg agc cag ggg 610
 Gly Gln Ile Leu Ser Lys Leu Arg Leu Ala Ser Pro Pro Ser Gln Gly
 55 60 65

gag gta ccg ccg ggc ccg ctg ccc gag gcg gtg ctc gct ttg tac aac 658
 Glu Val Pro Pro Gly Pro Leu Pro Glu Ala Val Leu Ala Leu Tyr Asn
 70 75 80

agc acc cgc gac cgg gtg gca ggc gag agc gct gac ccg gag ccc gag	706
Ser Thr Arg Asp Arg Val Ala Gly Glu Ser Ala Asp Pro Glu Pro Glu	
85 90 95	
ccc gag gcg gac tac tac gcc aaa gaa gtc acc cgc gtg cta atg gtg	754
Pro Glu Ala Asp Tyr Tyr Ala Lys Glu Val Thr Arg Val Leu Met Val	
100 105 110	
gac cgc aac aac gca atc tat gac aaa acc aaa gac atc aca cac agt	802
Asp Arg Asn Asn Ala Ile Tyr Asp Lys Thr Lys Asp Ile Thr His Ser	
115 120 125 130	
ata tat atg ttc ttc aat acg tca gac att cgg gaa gca gtg cca gaa	850
Ile Tyr Met Phe Phe Asn Thr Ser Asp Ile Arg Glu Ala Val Pro Glu	
135 140 145	
ccc cca ttg ctg tcc cgt gca gag ctg cgc ctg cag aga ttc aag tca	898
Pro Pro Leu Leu Ser Arg Ala Glu Leu Arg Leu Gln Arg Phe Lys Ser	
150 155 160	
act gtg gag caa cac gta gaa ctc tac cag aaa tat agc aac aat tcc	946
Thr Val Glu Gln His Val Glu Leu Tyr Gln Lys Tyr Ser Asn Asn Ser	
165 170 175	
tgg cgt tac ctt ggt aac cgg ctg ctg acc ccc act gat acg cct gag	994
Trp Arg Tyr Leu Gly Asn Arg Leu Leu Thr Pro Thr Asp Thr Pro Glu	
180 185 190	
tgg ctg tct ttt gac gtc act gga gtt gtc cgg cag tgg ctg aac caa	1042
Trp Leu Ser Phe Asp Val Thr Gly Val Val Arg Gln Trp Leu Asn Gln	
195 200 205 210	
gga gac gga ata cag ggc ttt cgc ttc agt gct cac tgc tct tgt gac	1090
Gly Asp Gly Ile Gln Gly Phe Arg Phe Ser Ala His Cys Ser Cys Asp	
215 220 225	
agc aaa gat aat gta ctc cac gtg gaa atc aat ggg atc agt ccc aaa	1138
Ser Lys Asp Asn Val Leu His Val Glu Ile Asn Gly Ile Ser Pro Lys	
230 235 240	
cgt cga ggt gac ctg ggc acc atc cat gac atg aac cga ccc ttc ctg	1186
Arg Arg Gly Asp Leu Gly Thr Ile His Asp Met Asn Arg Pro Phe Leu	
245 250 255	
ctc ctc atg gcc acc ccc ctg gaa agg gct caa cac ctg cac agc tcc	1234
Leu Leu Met Ala Thr Pro Leu Glu Arg Ala Gln His Leu His Ser Ser	
260 265 270	
agg cac cgg aga gcc ctg gat acc aac tac tgc ttc agc tcc aca gag	1282
Arg His Arg Arg Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu	
275 280 285 290	
aag aac tgc tgt gta cgg cag ctg tac att gac ttt agg aag gac ctg	1330
Lys Asn Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu	
295 300 305	
ggt tgg aag tgg atc cac gag ccc aag ggc tac cat gcc aac ttc tgt	1378
Gly Trp Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys	
310 315 320	
ctg ggg ccc tgc ccc tac att tgg agc ctg gac aca cag tac agc aag	1426
Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys	

325	330	335	
gtc ctt gcc ctc tac aac caa cac aac ccg ggt gct tcc gca tca ccg			1474
Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ser Pro			
340	345	350	
tgc tgc gtg ccg cag gct ttg gag cca ctg ccc atc gtc tac tac gtg			1522
Cys Cys Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val			
355	360	365	370
ggt cgc aag ccc aag gtg gag cag ttg tcc aac atg atc gtg cgc tcc			1570
Gly Arg Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser			
375	380	385	
tgc aag tgc agc tga			1585
Cys Lys Cys Ser *			
390			

<210> 28
 <211> 2745
 <212> DNA
 <213> Homo sapiens

<221> CDS
 <222> (842)...(2017)

<400> 28
 acctccctcc gcggagcagc cagacagcga gggccccggc cgggggcagg ggggacgccc 60
 cgtcgggggc accccccccg gctctgagcc gcccgcgggg ccggcctcgg cccggagcgg 120
 aggaaggagt cgccgaggag cagcctgagg cccagagtc tgagacgagc cgccgccgcc 180
 cccgccactg cggggaggag ggggaggagg agcgggagga gggacgagct ggtcgggaga 240
 agaggaaaaa aacttttgag acttttccgt tgccgctggg agccggaggc gcggggacct 300
 cttggcgcca cgctgccccg cgaggaggca ggacttgggg accccagacc gcctcccttt 360
 gccgcccggg acgcttgctc cctccctgcc ccctacacgg cgtccctcag gcgcccccat 420
 tccggaccag ccctcgggag tcgccgaccc ggcctcccgc aaagactttt cccagacct 480
 cgggcgcacc ccctgcacgc cgccttcate ccggcctgt ctctgagcc cccgcgcate 540
 ctagaccctt tctcctccag gagacggatc tctctccgac ctgccacaga tcccctattc 600
 aagaccaccc accttctggt accagatcgc gcccatctag gttatttccg tgggatactg 660
 agacaccccc ggtccaagcc tcccctccac cactgcgccc ttctccctga ggagcctcag 720
 ctttccctcg aggcctcct accttttgcc gggagacccc cagcccttgc agggggcgggg 780
 cctccccacc acaccagccc tggtcgcgct ctgggcagtg ccggggggcg ccgcctcccc 840
 c atg ccg ccc tcc ggg ctg cgg ctg ctg ccg ctg ctg cta ccg ctg ctg 889
 Met Pro Pro Ser Gly Leu Arg Leu Leu Pro Leu Leu Leu Pro Leu Leu
 1 5 10 15

tgg cta ctg gtg ctg acg cct ggc ccg ccg gcc gcg gga cta tcc acc	937
Trp Leu Leu Val Leu Thr Pro Gly Pro Pro Ala Ala Gly Leu Ser Thr	
20 25 30	

tgc aag act atc gac atg gag ctg gtg aag cgg aag cgc atc gag gcc	985
Cys Lys Thr Ile Asp Met Glu Leu Val Lys Arg Lys Arg Ile Glu Ala	
35 40 45	

atc cgc ggc cag atc ctg tcc aag ctg cgg ctc gcc agc ccc ccg agc	1033
---	------

WO 01/19161

PCT/US00/25272

Ile	Arg	Gly	Gln	Ile	Leu	Ser	Lys	Leu	Arg	Leu	Ala	Ser	Pro	Pro	Ser	
	50					55					60					
cag	ggg	gag	gtg	ccg	ccc	ggc	ccg	ctg	ccc	gag	gcc	gtg	ctc	gcc	ctg	1081
Gln	Gly	Glu	Val	Pro	Pro	Gly	Pro	Leu	Pro	Glu	Ala	Val	Leu	Ala	Leu	
65					70					75					80	
tac	aac	agc	acc	cgc	gac	cgg	gtg	gcc	ggg	gag	agt	gca	gaa	ccg	gag	1129
Tyr	Asn	Ser	Thr	Arg	Asp	Arg	Val	Ala	Gly	Glu	Ser	Ala	Glu	Pro	Glu	
				85					90					95		
ccc	gag	cct	gag	gcc	gac	tac	tac	gcc	aag	gag	gtc	acc	cgc	gtg	cta	1177
Pro	Glu	Pro	Glu	Ala	Asp	Tyr	Tyr	Ala	Lys	Glu	Val	Thr	Arg	Val	Leu	
			100					105					110			
atg	gtg	gaa	acc	cac	aac	gaa	atc	tat	gac	aag	ttc	aag	cag	agt	aca	1225
Met	Val	Glu	Thr	His	Asn	Glu	Ile	Tyr	Asp	Lys	Phe	Lys	Gln	Ser	Thr	
		115					120					125				
cac	agc	ata	tat	atg	ttc	ttc	aac	aca	tca	gag	ctc	cga	gaa	gcg	gta	1273
His	Ser	Ile	Tyr	Met	Phe	Phe	Asn	Thr	Ser	Glu	Leu	Arg	Glu	Ala	Val	
	130					135					140					
cct	gaa	ccc	gtg	ttg	ctc	tcc	cgg	gca	gag	ctg	cgt	ctg	ctg	agg	agg	1321
Pro	Glu	Pro	Val	Leu	Leu	Ser	Arg	Ala	Glu	Leu	Arg	Leu	Leu	Arg	Arg	
145					150					155					160	
ctc	aag	tta	aaa	gtg	gag	cag	cac	gtg	gag	ctg	tac	cag	aaa	tac	agc	1369
Leu	Lys	Leu	Lys	Val	Glu	Gln	His	Val	Glu	Leu	Tyr	Gln	Lys	Tyr	Ser	
				165					170					175		
aac	aat	tcc	tgg	cga	tac	ctc	agc	aac	cgg	ctg	ctg	gca	ccc	agc	gac	1417
Asn	Asn	Ser	Trp	Arg	Tyr	Leu	Ser	Asn	Arg	Leu	Leu	Ala	Pro	Ser	Asp	
			180					185					190			
tcg	cca	gag	tgg	tta	tct	ttt	gat	gtc	acc	gga	gtt	gtg	cgg	cag	tgg	1465
Ser	Pro	Glu	Trp	Leu	Ser	Phe	Asp	Val	Thr	Gly	Val	Val	Arg	Gln	Trp	
		195					200					205				
ttg	agc	cgt	gga	ggg	gaa	att	gag	ggc	ttt	cgc	ctt	agc	gcc	cac	tgc	1513
Leu	Ser	Arg	Gly	Gly	Glu	Ile	Glu	Gly	Phe	Arg	Leu	Ser	Ala	His	Cys	
	210					215					220					
tcc	tgt	gac	agc	agg	gat	aac	aca	ctg	caa	gtg	gac	atc	aac	ggg	ttc	1561
Ser	Cys	Asp	Ser	Arg	Asp	Asn	Thr	Leu	Gln	Val	Asp	Ile	Asn	Gly	Phe	
225					230					235					240	
act	acc	ggc	cgc	cga	ggt	gac	ctg	gcc	acc	att	cat	ggc	atg	aac	cgg	1609
Thr	Thr	Gly	Arg	Arg	Gly	Asp	Leu	Ala	Thr	Ile	His	Gly	Met	Asn	Arg	
				245					250					255		
cct	ttc	ctg	ctt	ctc	atg	gcc	acc	ccg	ctg	gag	agg	gcc	cag	cat	ctg	1657
Pro	Phe	Leu	Leu	Leu	Met	Ala	Thr	Pro	Leu	Glu	Arg	Ala	Gln	His	Leu	
			260					265					270			
caa	agc	tcc	cgg	cac	cgc	cga	gcc	ctg	gac	acc	aac	tat	tgc	ttc	agc	1705
Gln	Ser	Ser	Arg	His	Arg	Arg	Ala	Leu	Asp	Thr	Asn	Tyr	Cys	Phe	Ser	
		275					280					285				
tcc	acg	gag	aag	aac	tgc	tgc	gtg	cgg	cag	ctg	tac	att	gac	ttc	cgc	1753
Ser	Thr	Glu	Lys	Asn	Cys	Cys	Val	Arg	Gln	Leu	Tyr	Ile	Asp	Phe	Arg	
	290					295					300					

WO 01/19161

PCT/US00/25272

aag gac ctc ggc tgg aag tgg atc cac gag ccc aag ggc tac cat gcc 1801
 Lys Asp Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala
 305 310 315 320

aac ttc tgc ctc ggg ccc tgc ccc tac att tgg agc ctg gac acg cag 1849
 Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln
 325 330 335

tac agc aag gtc ctg gcc ctg tac aac cag cat aac ccg ggc gcc tcg 1897
 Tyr Ser Lys Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser
 340 345 350

gcg gcg ccg tgc tgc gtg ccg cag gcg ctg gag ccg ctg ccc atc gtg 1945
 Ala Ala Pro Cys Cys Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val
 355 360 365

tac tac gtg ggc cgc aag ccc aag gtg gag cag ctg tcc aac atg atc 1993
 Tyr Tyr Val Gly Arg Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile
 370 375 380

gtg cgc tcc tgc aag tgc agc tga ggccccgccc cgccccgccc cgccccggca 2047
 Val Arg Ser Cys Lys Cys Ser *
 385 390

ggccccggccc caccgccc cgccccgct gccttgccca tgggggctgt atttaaggac 2107
 accgtgcccc aagcccacct ggggccccat taaagatgga gagaggactg cggatctctg 2167
 tgtcattggg cgctgcctg gggctcccat ccctgacgtt cccccactcc cactccctct 2227
 ctctccctct ctgcctctc ctgcctgtct gcactattcc tttgcccggc atcaaggcac 2287
 aggggaccag tggggaacac tactgtagtt agatctatctt attgagcacc ttgggcactg 2347
 ttgaagtgcc ttacattaat gaactcatte agtcaccata gcaacactct gagatggcag 2407
 ggactctgat aacacccatt ttaaagggtg aggaacaag cccagagagg ttaaggagg 2467
 agttcctgcc caccaggaac ctgctttagt gggggatagt gaagaagaca ataaaagata 2527
 gtagttcagg ccaggcgggg tgctcacgcc tgtaatccta gcacttttgg gaggcagaga 2587
 tgggaggata cttgaatcca ggcatttgag accagcctgg gtaacatagt gagaccctat 2647
 ctctacaaaa cactttttaa aaatgtacac ctgtggtccc agctactctg gaggctaagg 2707
 tgggaggatc acttgatcct gggaggtcaa ggctgcag 2745

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29

cgactccttc ctccgctccg

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30

ctcgtccctc ctcccgtcc

20

<210> 31
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 31
 aagtcctgcc tcctcgcggg 20

 <210> 32
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 32
 aagggtctag gatgcgcggg 20

 <210> 33
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 33
 ctcagggaga agggcgcgagt 20

 <210> 34
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 34
 gcactgccga gagcgcggaac 20

 <210> 35
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 35
 gtagcagcag cggcagcagc 20

 <210> 36
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 36
 atggcctcga tgcgcttccg 20

 <210> 37
 <211> 20
 <212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37

gcgtagtagt cggcctcagg

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38

accactgccg cacaactccg

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39

tcggcggccg gtagtgaacc

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40

gaagttggca tggtagccct

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41

ggcgcccggg ttatgctggt

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

ctccaccttg ggcttgcggc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
aatgacacag agatccgcag 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
tagatctaac tacagtagtg 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
cgcttggcct gaactactat 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
cccaggctgg tctcaaatgc 20

<210> 47
<211> 4267
<212> DNA
<213> Mus musculus

<221> CDS
<222> (1218) ... (2462)

<400> 47
ggttatctgc tggcagcagg ttgctcgga gcagagctgc tgaaactgcc ggcaggagag 60
cgagtgggag agaaagagag aaggcgctga gagctgagct ctgggggcagg cgtcagggat 120
ggagagaagt attagggttt aaagagccat tctggagcaa cccatctgcg gagagaagga 180
tcggcagagg tctattttag ggtcgcaagt acctacttac cctaagcgag aaagtgcaac 240
cttgggtgga gctaggagaa gctaggggaag ggtgagagtc ccgggggcagc ccgcagccaa 300
cgcgcccagg aggcggtggt gttccacagg ggttaaggag gtggccgacg gctgtcgccc 360
ttggccgcct ggagcaagaa aaggaggatc tgaaggaccg agctggaggc tggccctctt 420
tgcaggcagc agcggcggtc gcaacgtgga gcgacccagc cgggtgtagg ccacagcgcg 480
gccggcagga gcgggatcct cgccgcctgc tccggcctct gtggatctcc ggggcgagaca 540
gtatcccacc gagtctccga gtgagccgct ccggggcgca tctgcctccc cgcggtctcg 600
caggctcgcc ctcggcgcgc gcgcacgcac gcgcgcacac gcgcacacat ccacacgcac 660
actcatccac acacgtgtgg aaggcagggc cgagccgctc ggtctttgaa cttctcagtt 720
agagcccggc gcagccccgg ccgcccgtca gcgctccccg cggccctgcg tgcctcctgc 780

15

WO 01/19161

PCT/US00/25272

Thr 205	Asp	Ala	Val	Gln	Glu	Trp 210	Leu	His	His	Lys	Asp 215	Arg	Asn	Leu	Gly	
ttt Phe 220	aaa Lys	ata Ile	agt Ser	tta Leu	cac His 225	tgc Cys	ccc Pro	tgc Cys	tgt Cys	acc Thr 230	ttc Phe	gtg Val	ccg Pro	tct Ser	aat Asn 235	1922
aat Asn	tac Tyr	atc Ile	atc Ile	ccg Pro 240	aat Asn	aaa Lys	agc Ser	gaa Glu	gag Glu 245	ctc Leu	gag Glu	gcg Ala	aga Arg	ttt Phe 250	gca Ala	1970
ggg Gly	att Ile	gat Asp	ggc Gly 255	acc Thr	tct Ser	aca Thr	tat Tyr	gcc Ala 260	agt Ser	ggg Gly	gat Asp	cag Gln	aaa Lys 265	act Thr	ata Ile	2018
aag Lys	tcc Ser	act Thr 270	agg Arg	aaa Lys	aaa Lys	acc Thr	agt Ser 275	ggg Gly	aag Lys	acc Thr	cca Pro	cat His 280	ctc Leu	ctg Leu	cta Leu	2066
atg Met	ttg Leu 285	ttg Leu	ccc Pro	tcc Ser	tac Tyr	aga Arg 290	ctg Leu	gag Glu	tca Ser	caa Gln 295	cag Gln	tcc Ser	agc Ser	cgg Arg	cgg Arg	2114
aag Lys 300	aag Lys	cgc Arg	gct Ala	ttg Leu	gat Asp 305	gct Ala	gcc Ala	tac Tyr	tgc Cys	ttt Phe 310	aga Arg	aat Asn	gtg Val	cag Gln	gat Asp 315	2162
aat Asn	tgc Cys	tgc Cys	ctt Leu	cgc Arg 320	cct Pro	ctt Leu	tac Tyr	att Ile	gat Asp 325	ttt Phe	aag Lys	agg Arg	gat Asp	ctt Leu 330	gga Gly	2210
tgg Trp	aaa Lys	tgg Trp	atc Ile 335	cat His	gaa Glu	ccc Pro	aaa Lys	ggg Gly 340	tac Tyr	aat Asn	gct Ala	aac Asn	ttc Phe 345	tgt Cys	gct Ala	2258
ggg Gly	gca Ala 350	tgc Cys	cca Pro	tat Tyr	cta Leu	tgg Trp	agt Ser 355	tca Ser	gac Asp	act Thr	caa Gln 360	cac His	acc Thr	aaa Lys	gtc Val	2306
ctc Leu 365	agc Ser	ctg Leu	tac Tyr	aac Asn	acc Thr	ata Ile 370	aat Asn	ccc Pro	gaa Glu	gct Ala	tcc Ser 375	gct Ala	tcc Ser	cct Pro	tgc Cys	2354
tgt Cys 380	gtg Val	tcc Ser	cag Gln	gat Asp	ctg Leu 385	gaa Glu	cca Pro	ctg Leu	acc Thr	att Ile 390	ctc Leu	tat Tyr	tac Tyr	att Ile	gga Gly 395	2402
aat Asn	acg Thr	ccc Pro	aag Lys	atc Ile 400	gaa Glu	cag Gln	ctt Leu	tcc Ser	aat Asn 405	atg Met	att Ile	gtc Val	aag Lys	tct Ser 410	tgt Cys	2450
aaa Lys	tgc Cys	agc Ser	taa *	agtccttggg	aaagccagga	cacgaaaatc	acggtgacaa									2502

tgacatatataa tgacaacgat gacgaccatg atgtttgtga caggagggag ggagttttga 2562
 ttcatcagtg tttaaaaaaa aaaaaattgg agaaaaaaa tcggtactag ttcaaacatt 2622
 ttgcaagctt gtgttctggt tggttaaaact ggcattctgag attacagcaa caacaaccac 2682
 aaaaatggaa ggcgttagtc tgcattctcac ctacttccta agagacacaa aaagaaaaca 2742
 tctttttttt tttaaggaaa aaaataaaca ctggaagaat ttgttagtgt taattatgtg 2802
 aaaaaaaaaa aacatcaaaa caaacagga aaatccgttc agtggagttg tacgtattgt 2862

```

ttccagcccg catttcaccc cagcctctc ctggttcctc tgtattgctc tctgcagtgg 2922
gtgccctccc cgtcccttcc tccaagctaa cagtgggtta tttattgtgt gttactatat 2982
aatgaacctt tcattaccct tggaaaacaa aacaggtgta taaatcgaga ccaaatactt 3042
tgccacaaac tcatggatgg cttaaggagt ttgaactcaa ataagccagg ggggaaggagg 3102
tcatagtgga tgacccctg tgagttgtta taggactaag caagtcttct gtggaaaaat 3162
caaagcccca gcaaacacgt gtctgccgaa gcttcatgga cgccatatgc ccagaaggcc 3222
tgттаааааа gaaaacttgg aatcagtggc aatctggaag attttttttt ccttttaatt 3282
gtaaatgggt ctttgccagt ttaagcaagc cggtgaaatg ttgacctgtt ttgatatgta 3342
ttgtcagact tttgaccgtg aagtggctgt tgatctacaa tacaggtttt tcctttgtct 3402
tggtatatgt aattacatgg atactattaa aatagacggg tctagaagcc agcatgattg 3462
aaaacacact gcagatctgt tttccaaac tattaaatcg aaacagtaac tactttacat 3522
gtaatgtgta gatcttacca catttttaat attctgtaat aatggttatg atttagattg 3582
aacttaaatt tggacttttt tttttaatga tcattcagat tgtatatattg tttccttttag 3642
ctggccagta ctttgaata aaaccctag attttgactt gcactacaaa ttcaattttt 3702
tttatatact atcttccctg cctgtatttt atgtattgtc catttaatga catgagctac 3762
ctgggtccat tcctcccca accccagttc cttctatttt ccaaaagata aaaaccaaag 3822
cccaaaaagc taggtttgag ctccacagtg tttcagcctt ttctgcgtca gtgtgagtca 3882
tgtggcgggt gagcgggtggg gcttctggga tggatggttc tgtgtgaaca cagaagttcg 3942
caciaatgta ggcttagcta gggtttaaga atctcaactc agagtcttag tgactgggct 4002
aggaaaagtt tctttaactc ctatatattat ggactctctt tgccgttcaa aagcagacag 4062
ttcaaaggaa gcaccttttt ctttaattgg tttttttggg gctcatgggg tgtattaaaa 4122
gacacacagt ttggttgagt ttttcaaagg gggaaaaagt ccaggccagc actcgtcatt 4182
ttattcataa tttcatccat tatttccctg atttcattga aatacagggt ttgaaagaca 4242
ttctttgcag gctgattaaa aaaaa 4267

```

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 48

gccggcagtt tcagcagctc

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 49

ctcgcaccct tcctagctt

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

WO 01/19161

PCT/US00/25272

<400> 50
 tttcttgctc caggcggcca 20

<210> 51
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 51
 gagcaggcgg cgaggatccc 20

<210> 52
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 52
 gccctgcctt ccacacgtgt 20

<210> 53
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 53
 gtgcggagtg gctgatctga 20

<210> 54
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 54
 aaaatgcaac gcgttcccaa 20

<210> 55
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 55
 ccgggaccag atgcaggagc 20

<210> 56
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 56
 tccggcttgc cttctcctgc 20

WO 01/19161

PCT/US00/25272

<210> 57
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 57
 gggttttgca agcggaagac 20

<210> 58
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 58
 cgatgtagcg ctgggtggga 20

<210> 59
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 59
 ggtcttccca ctggtttttt 20

<210> 60
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 60
 aagcttcggg atttatggtg 20

<210> 61
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 61
 accgtgattt tcgtgtcctg 20

<210> 62
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 62
 gcgggctgga aacaatacgt 20

<210> 63
 <211> 20
 <212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 63

cccctggcctt atttgagttc

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 64

accggcttgc ttaaactggc

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 65

cagccacttc acggtcaaaa

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 66

atggacccag gtagctcatg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 67

cacccgccac atgactcaca

20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 68

tacaccccat gagcaccaaa

20

- 74 -

What is claimed is:

1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding TGF- β 1, wherein said compound comprises at least a portion of a
5 sequence selected from the group consisting of SEQ ID NO:2, 3, 4, 5, 7, 9, 13, 14, 15, 16, 18, 21, 22, 23, 26, 34, 36, 37, 41, 42, 43, or 45 and wherein said compound modulates the expression of TGF- β 1.
2. The compound of claim 1 which is an antisense
10 oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified
15 internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 20 6. The compound of claim 5 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 25 8. The compound of claim 7 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 30 10. A composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier or diluent.
11. The composition of claim 10 further comprising a colloidal dispersion system.

-75-

12. The composition of claim 10 wherein the compound is an antisense oligonucleotide.

13. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding TGF- β 2,
5 wherein said compound comprises at least a portion of a sequence selected from the group consisting of SEQ ID NO:53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65 or 66 and wherein said compound modulates the expression of TGF- β 2.

14. The compound of claim 13 which is an antisense
10 oligonucleotide.

15. The compound of claim 14 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

16. The compound of claim 15 wherein the modified
15 internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.

17. The compound of claim 14 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

20 18. The compound of claim 17 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.

19. The compound of claim 14 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

25 20. The compound of claim 19 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.

21. The compound of claim 14 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

30 22. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

23. The composition of claim 22 further comprising a colloidal dispersion system.

-76-

24. The composition of claim 22 wherein the compound is an antisense oligonucleotide.

25. A method of inhibiting the expression of TGF- β 1 in cells or tissues comprising contacting said cells or
5 tissues with the compound of claim 1 so that expression of TGF- β 1 is inhibited.

26. A method of inhibiting the expression of TGF- β 2 in cells or tissues comprising contacting said cells or
tissues with the compound of claim 13 so that expression of
10 TGF- β 2 is inhibited.

27. A method of treating an animal having a disease or condition associated with TGF- β 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim
15 1 so that expression of TGF- β 1 is inhibited.

28. The method of claim 27 wherein said disease or condition is inflammation.

29. The method of claim 27 wherein said disease or condition is fibrosis or a fibrotic disease or condition.

20 30. The method of claim 29 wherein said fibrotic disease or condition is fibrotic scarring, peritoneal adhesions, lung fibrosis or conjunctival scarring.

31. A method of treating an animal having a disease or condition associated with TGF- β 2 comprising
25 administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 13 so that expression of TGF- β 2 is inhibited.

32. The method of claim 31 wherein said disease or condition is inflammation.

30 33. The method of claim 31 wherein said disease or condition is fibrosis or a fibrotic disease or condition.

34. The method of claim 33 wherein said fibrotic disease or condition is fibrotic scarring, peritoneal adhesions, lung fibrosis or conjunctival scarring.